Reuters – Actelion, Europe’s largest biotech company, squares up to hedge fund Elliott Advisors at its annual general meeting on Thursday and hopes shareholders will back board candidates it has proposed.
New York-based fund Elliott, which is urging Actelion to consider putting itself up for sale after a string of product setbacks, has also nominated candidates it will ask shareholders to consider in order to implement new strategy.
